510(k) device
ScreenDx
Imvaria, Inc. · Radiology Software For Referral Of Findings Related To Fibrotic Lung Disease. (QWO, Class II) · First FDA decision Jan 10, 2025, newest Jan 10, 2025
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "ScreenDx"
MAUDE reports
0
Brand "ScreenDx", since 2015
PubMed studies
3
Mentioning "ScreenDx"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing ScreenDx
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- ScreenDx510(k)
K241891 · Decided Jan 10, 2025 · 196 days after receipt
Device type: Radiology Software For Referral Of Findings Related To Fibrotic Lung Disease. (QWO) · Radiology & Imaging
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Hospice Alzheimer's Disease & Related DisordersLocal determinationIn effectL34567Palmetto GBAUpdated Feb 23, 2024
Clinical trials
Device studies on ClinicalTrials.gov that name "ScreenDx", any status and sponsor, newest update first.
No registered device study names "ScreenDx".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "ScreenDx", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QWO
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "ScreenDx"[tiab]. The summary above synthesizes these.
- Automated artificial intelligence detection of early or under-diagnosed interstitial lung disease by computed tomography in the COPDGene trial.
Chen SJ, Kalra A, Muelly M, et al. · Respir Med · 2025
- Computer-Aided Pulmonary Fibrosis Detection Leveraging an Advanced Artificial Intelligence Triage and Notification Software.
Selvan KC, Kalra A, Reicher J, et al. · J Clin Med Res · 2023
- ScreenDx, an artificial intelligence-based algorithm for the incidental detection of pulmonary fibrosis.
Touloumes N, Gagianas G, Bradley J, et al. · Am J Med Sci · 2025Research Support, N.I.H., Extramural
Other devices of this type
Also filed under product code QWO.
- Fibresolve (with PCCP)Imvaria, Inc. · De Novo 2025
- Iq-UipImbio, Inc. · 510(k) 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.